|  | RFS | BCSS | ||
---|---|---|---|---|---|
Variable | No. | Hazard ratio (95Â % CI) | P | Hazard ratio (95Â % CI) | P |
Age | 215 | 1.16 (0.46–2.98) | NS | 1.11 (0.39–3.16) | NS |
pT stagea | 215 | Â | Â | Â | Â |
 T0 |  | 1.0 |  | 1.0 |  |
 T1 |  | 1.58 (0.46–5.46) | NS | 1.54 (0.34–7.06) | NS |
 T2 |  | 2.12 (0.61–7.37) | NS | 2.30 (0.51–10.41) | NS |
 T3 |  | 7.80 (1.74–34.97) | <0.01 | 11.29(2.06–61.89) | <0.01 |
 T4 |  | 2.64 (0.53–13.10) | NS | 8.95 (1.73–46.29) | <0.01 |
pN stagea | 215 | Â | Â | Â | Â |
 N0 |  | 1.0 |  | 1.0 |  |
 N1 |  | 1.77 (0.66–4.74) | NS | 2.38 (0.69–8.23) | NS |
 N2 and N3 |  | 2.75 (1.01–7.56) | <0.05 | 4.61 (1.32–16.08) | <0.05 |
pTNMa | 215 | Â | Â | Â | Â |
 0–1 |  | 1.0 |  | 1.0 |  |
 2 |  | 1.15 (0.41–3.22) | NS | 1.63 (0.50–5.30) | NS |
 3–4 |  | 3.41 (1.39–8.35) | <0.01 | 3.92 (1.33–11.54) | <0.05 |
HG | 215 | Â | Â | Â | Â |
 1 |  | 1.0 |  | 1.0 |  |
 2 |  | 2.68 (0.56–12.89) | NS | 1.65 (0.30–9.01) | NS |
 3 |  | 26.29(6.25–10.57) | <0.001 | 21.70(5.11–92.12) | <0.001 |
Hormone receptor | 215 | Â | Â | Â | Â |
 ER+ PR+ |  | 1.0 |  | 1.0 |  |
 ER+ or PR+ |  | 1.88 (0.93–3.82) | NS | 2.05 (0.94–4.50) | NS |
 ER− PR− |  | 1.76 (0.76–4.08) | NS | 1.95 (0.77–4.89) | NS |
Her2 | 215 | Â | Â | Â | Â |
 + |  | 0.84 (0.43–1.66) | NS | 1.14 (0.56–2.34) | NS |
 - |  | 1.0 |  | 1.0 |  |
Molecular subtype | 215 | Â | Â | Â | Â |
 Luminal A |  | 1.0 |  | 1.0 |  |
 Luminal B |  | 1.12 (0.53–2.39) | NS | 1.32 (0.58–3.00) | NS |
 HER2-enriched |  | 0.81 (0.24–2.71) | NS | 1.04 (0.30–3.58) | NS |
 Triple-negative |  | 2.07 (0.78–5.50) | NS | 2.11 (0.70–6.33) | NS |
pCR | 215 | Â | Â | Â | Â |
 Yes |  | 1.0 |  | 1.0 |  |
 No |  | 3.00 (1.92–9.73) | <0.05 | 9.05 (1.24–65.97) | <0.05 |
Chemotherapy regimen | 215 | Â | Â | Â | Â |
 TEC |  | 1.0 |  | 1.0 |  |
 TCH |  | 0.89 (0.67-2.93) | NS | 1.65 (0.54-3.42) | NS |
 TC |  | 1.19 (0.86–2.25) | NS | 1.32 (0.42–2.91) | NS |
 EC |  | 1.23 (0.63–2.40) | NS | 1.20 (0.58–2.48) | NS |
Surgery | 215 | Â | Â | Â | Â |
 Breast-conserving surgery |  | 1.0 |  | 1.0 |  |
 Modified mastectomy |  | 0.55 (0.27–1.10) | NS | 0.46 (0.21–1.03) | NS |
Chemotherapy cycles | 215 | Â | Â | Â | Â |
 3 |  | 1.0 |  | 1.0 |  |
 4 |  | 1.15 (0.52–2.54) | NS | 1.07 (0.47–2.48) | NS |
 >4 |  | 0.64 (0.17–2.42) | NS | 0.76 (0.20–2.88) | NS |
NLR | 215 | Â | Â | Â | Â |
 NLR < 2.1 |  | 1.0 |  | 1.0 |  |
 NLR ≥ 2.1 |  | 2.11 (1.09–4.11) | <0.05 | 2.45 (1.13–5.31) | <0.05 |
CRP (before NAC) | 215 | 1.03 (1.01–1.05) | <0.001 | 1.03 (1.01–1.06) | <0.01 |